Pulse Biosciences, Inc (PLSE) Stock Analysis

Q: What is the PLSE stock price target?

Take-profit $25.50 (+24.8% upside). Prior stop was $19.01.

Q: Is PLSE overvalued or undervalued?

Pulse Biosciences, Inc trades at a P/E of N/A (forward -23.5). TrendMatrix value score: 5.0/10. Overall verdict: Sell.

Q: What do analysts say about PLSE?

8 analysts cover PLSE with a consensus score of 4.3/5. Average price target: $30.

Range Bound setup

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Medical Instruments & Supplies

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $20.40: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.

$20.40+24.8% A.UpsideScore 4.1/10#25 of 25 Medical Instruments & Supplies

Stop $19.01Target $25.50(analyst − 15%)A.R:R 1.8:1

Analyst target$30.00+47.1%2 analysts

Range unavailable (2 analysts)

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.7 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-23.5

Mkt Cap$1.4B

EV/EBITDA-17.1

Profit Mgn0.0%

ROE-74.4%

Rev Growth—

Beta1.69

DividendNone

Rating analysts8

Quality Signals

Piotroski F2/9

Options Flow

P/C0.14bullish

IV118%elevated

Max Pain$18-11.8% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.015%0.75

Quality1.715%0.26

Growth5.015%0.75

Momentum2.110%0.21

Sentiment8.210%0.82

Insider Activity3.310%0.33

Peer Rank2.610%0.26

Technical Setup6.05%0.30

Risk Profile2.45%0.12

Catalyst5.85%0.29

Overall (Σ contributions)4.08

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -8433% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

4.0

Rsi

5.5

Volume distribution (falling OBV)Above 200-day MA

Volatile — 7.0% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Implied Vol

0.0

Debt Equity

0.0

Short Interest

1.9

Max Pain Risk

3.0

Beta

4.4

Put Call

10.0

High short interest justified: 16%High IV: 118%Above max pain $18

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.4

Value Rank

5.0

Growth Rank

5.0

GatesMomentum 2.1<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

58 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $17.75Resistance $24.84

Price Targets

$19

$26

A.Upside+25.0%

A.R:R1.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.7 < 4.0)

! Momentum score 2.1/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:7d<=7d

Earnings

3/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PLSE stock a buy right now?

Sell if holding. Engine safety override at $20.40: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $19.01. Score 4.1/10, moderate confidence.

What is the PLSE stock price target?

Take-profit target: $25.50 (+24.8% upside). Prior stop was $19.01. Stop-loss: $19.01.

What are the risks of investing in PLSE?

Quality below floor (1.7 < 4.0).

Is PLSE overvalued or undervalued?

Pulse Biosciences, Inc trades at a P/E of N/A (forward -23.5). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about PLSE?

8 analysts cover PLSE with a consensus score of 4.3/5. Average price target: $30.

What does Pulse Biosciences, Inc do?Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond...

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.